EGFR exon 18 G719X (G719A/C/S) is an "uncommon" sensitizing mutation (~3% of EGFR-mut NSC...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-EGFR-G719X-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-EGFR-MUTATION |
|---|---|
| Variant | exon 18 G719X |
| Disease | DIS-NSCLC |
| ESCAT tier | IB |
| Recommended combinations | afatinib monotherapy, osimertinib monotherapy |
| Evidence summary | EGFR exon 18 G719X (G719A/C/S) is an "uncommon" sensitizing mutation (~3% of EGFR-mut NSCLC). Afatinib (LUX-Lung pooled analysis, Yang 2015) shows highest activity in G719X; osimertinib also active (UNICORN, Ahn 2022). Often co-occurs with S768I or L861Q. |
Notes
ESCAT IB (tumor-specific approval, randomized evidence pooled). Compound mutations (G719X+S768I, G719X+L861Q) often respond well to afatinib. Universal NGS for EGFR uncommon-mutation detection.
Used By
No reverse references found in the YAML corpus.